Immunogen's phase 3 ADC survival data spook investors, sending stock down ahead of FDA filing

Immunogen’s full data on mirvetuximab soravtansine have underwhelmed investors. While the biotech is racing to the FDA with the results, its stock fell around 20% to below $5 in premarket trading after the release of survival data that fell short of investor expectations.